Omeros Corporation (OMER)
Largest Insider Buys in Sector
OMER Stock Price History Chart
OMER Stock Performance
About Omeros Corporation
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Insider Activity of Omeros Corporation
Over the last 12 months, insiders at Omeros Corporation have bought $40,500 and sold $0 worth of Omeros Corporation stock.
On average, over the past 5 years, insiders at Omeros Corporation have bought $40,500 and sold $1.61M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Demopulos Gregory A MD (Chairman, CEO & President) — $25,200. Demopulos Peter A MD (director) — $15,300.
The last purchase of 15,000 shares for transaction amount of $25,200 was made by Demopulos Gregory A MD (Chairman, CEO & President) on 2023‑11‑17.
List of Insider Buy and Sell Transactions, Omeros Corporation
| 2023-11-17 | Demopulos Gregory A MD | Chairman, CEO & President | 15,000 0.0245% | $1.68 | $25,200 | +111.66% | ||
| 2023-11-15 | Demopulos Peter A MD | director | 10,000 0.0161% | $1.53 | $15,300 | +125.57% | ||
| 2023-05-22 | Sale | Cable Thomas J. | director | 5,000 0.0081% | $6.53 | $32,650 | -45.85% | |
| 2023-05-22 | Sale | HANISH ARNOLD C | director | 5,000 0.008% | $6.46 | $32,300 | -45.85% | |
| 2021-06-17 | Sale | Demopulos Gregory A MD | CHAIRMAN, CEO & PRESIDENT | 36,857 0.0588% | $14.90 | $549,169 | -53.84% | |
| 2021-06-15 | Sale | Demopulos Gregory A MD | CHAIRMAN, CEO & PRESIDENT | 36,856 0.0596% | $15.02 | $553,577 | -53.29% | |
| 2021-05-20 | Sale | Demopulos Gregory A MD | CHAIRMAN, CEO & PRESIDENT | 36,856 0.0584% | $14.96 | $551,366 | -51.92% | |
| 2021-05-19 | Sale | Demopulos Gregory A MD | CHAIRMAN, CEO & PRESIDENT | 36,857 0.0594% | $17.07 | $629,149 | -57.10% | |
| 2021-04-08 | Sale | Demopulos Gregory A MD | CHAIRMAN, CEO & PRESIDENT | 35,206 0.0566% | $17.76 | $625,259 | -53.90% | |
| 2021-04-07 | Sale | Demopulos Gregory A MD | CHAIRMAN, CEO & PRESIDENT | 37,407 0.0599% | $17.91 | $669,959 | -54.24% | |
| 2021-02-22 | Sale | JACOBSEN MICHAEL A | VP FINANCE AND CAO | 8,100 0.0134% | $23.28 | $188,568 | -34.89% | |
| 2021-02-19 | Sale | JACOBSEN MICHAEL A | VP FINANCE AND CAO | 10,000 0.0155% | $22.64 | $226,400 | -37.23% | |
| 2021-02-10 | Sale | JACOBSEN MICHAEL A | VP FINANCE AND CAO | 1,900 0.0031% | $22.49 | $42,731 | -32.76% | |
| 2021-01-19 | Sale | JACOBSEN MICHAEL A | VP FINANCE AND CAO | 9,500 0.0157% | $19.95 | $189,525 | -21.58% | |
| 2021-01-13 | Sale | Cable Thomas J. | director | 5,000 0.008% | $16.97 | $84,850 | -10.19% | |
| 2020-05-13 | Sale | Cable Thomas J. | director | 5,000 0.0093% | $14.40 | $71,999 | +4.28% | |
| 2019-12-03 | Sale | Cable Thomas J. | director | 20,000 0.0309% | $10.99 | $219,748 | -6.68% | |
| 2019-10-14 | Sale | Cable Thomas J. | director | 10,000 0.0205% | $15.12 | $151,180 | -7.99% | |
| 2018-08-31 | Sale | Kelbon Marcia S. | VP Patent and General Counsel | 15,058 0.0308% | $25.75 | $387,691 | -39.01% | |
| 2018-08-30 | Sale | Kelbon Marcia S. | VP Patent and General Counsel | 70,000 0.0825% | $14.28 | $999,250 | -36.44% |
Insider Historical Profitability
| Demopulos Peter A MD | director | 208516 0.3317% | $3.82 | 7 | 0 | <0.0001% |
| Demopulos Gregory A MD | Chairman, CEO & President | 123945 0.1972% | $3.82 | 1 | 12 | |
| Kelbon Marcia S. | VP Patent and General Counsel | 192645 0.3064% | $3.82 | 0 | 17 | |
| Aspiri Ray | director | 186872 0.2973% | $3.82 | 1 | 0 | <0.0001% |
| Cable Thomas J. | director | 35067 0.0558% | $3.82 | 0 | 20 | |
| JACOBSEN MICHAEL A | VP FINANCE AND CAO | 14000 0.0223% | $3.82 | 0 | 11 | |
| HANISH ARNOLD C | director | 0 0% | $3.82 | 1 | 1 | +0.81% |
Institutional Investor Ownership
| Ingalls Snyder Llc | $16.21M | 8.11 | 4.7M | +3.33% | +$522,267.54 | 0.76 | |
| BlackRock | $14.53M | 7.27 | 4.21M | -1.61% | -$237,063.30 | <0.0001 | |
| The Vanguard Group | $11.21M | 5.61 | 3.25M | +2.57% | +$280,650.60 | <0.0001 | |
| Stifel | $6.59M | 3.3 | 1.91M | +0.98% | +$63,669.86 | 0.01 | |
| D. E. Shaw & Co. | $5.79M | 2.9 | 1.68M | +12.42% | +$639,560.96 | 0.01 | |
| Geode Capital Management | $4.75M | 2.38 | 1.38M | +2.94% | +$135,821.75 | <0.0001 | |
| State Street | $4.27M | 2.13 | 1.24M | +2.99% | +$123,951.59 | <0.0001 | |
| Ci Private Wealth Llc | $2.15M | 1.08 | 623,663 | -6.03% | -$137,999.98 | <0.01 | |
| Bank of Montreal | $1.98M | 0.97 | 563,096 | 0% | +$0 | <0.01 | |
| Northern Trust | $1.91M | 0.96 | 554,108 | -0.88% | -$17,056.80 | <0.0001 | |
| UBS | $1.86M | 0.93 | 538,682 | +8.93% | +$152,269.21 | <0.01 | |
| Royal Bank of Canada | $1.85M | 0.93 | 537,232 | +5.56% | +$97,636.34 | <0.0001 | |
| Charles Schwab | $1.74M | 0.87 | 504,369 | +7.5% | +$121,422.75 | <0.0001 | |
| Nomura Holdings | $1.56M | 0.78 | 450,829 | +17.67% | +$233,513.24 | 0.01 | |
| Morgan Stanley | $743,638.00 | 0.37 | 215,547 | -23.68% | -$230,660.36 | <0.0001 | |
| BNY Mellon | $646,870.00 | 0.32 | 187,499 | -7.32% | -$51,111.63 | <0.0001 | |
| Wellington Management Company | $616,923.00 | 0.31 | 178,818 | New | +$616,923.00 | <0.0001 | |
| First Trust | $614,589.00 | 0.31 | 178,142 | +3.12% | +$18,585.12 | <0.01 | |
| Bridgeway Capital Management | $556,485.00 | 0.28 | 161,300 | -13.42% | -$86,250.00 | 0.01 | |
| Susquehanna Fundamental Investments Llc | $538,052.00 | 0.27 | 155,957 | New | +$538,052.00 | 0.03 | |
| Ameriprise Financial | $412,089.00 | 0.21 | 119,446 | +2.34% | +$9,418.51 | <0.0001 | |
| Ancora Advisors Llc | $408,942.00 | 0.21 | 118,534 | -27.29% | -$153,486.94 | 0.01 | |
| Group One Trading | $383,840.00 | 0.19 | 111,258 | -51.81% | -$412,602.64 | 0.01 | |
| Bank of America | $379,456.00 | 0.19 | 109,987 | -35.38% | -$207,773.27 | <0.0001 | |
| RhumbLine Advisers | $363,420.00 | 0.18 | 105,343 | -3.43% | -$12,902.53 | <0.0001 | |
| OZ MANAGEMENT LLC | $331,200.00 | 0.17 | 96,000 | New | +$331,200.00 | 0.01 | |
| Badgley Phelps Wealth Managers Llc | $271,019.00 | 0.14 | 78,556 | 0% | +$0 | 0.01 | |
| Barclays | $268,000.00 | 0.13 | 77,643 | -34.46% | -$140,912.02 | <0.0001 | |
| Simplex Trading Llc | $250,000.00 | 0.13 | 72,477 | New | +$250,000.00 | 0.01 | |
| American Financial Group | $221,000.00 | 0.11 | 64,113 | 0% | +$0 | 0.1 | |
| Sheaff Brock Investment Advisors | $207,432.00 | 0.1 | 60,125 | 0% | +$0 | 0.02 | |
| Hightower Advisors | $190,000.00 | 0.1 | 55,339 | -1.77% | -$3,433.38 | <0.0001 | |
| Two Sigma | $189,467.00 | 0.1 | 54,918 | +15.37% | +$25,247.09 | <0.0001 | |
| Nuveen | $190,599.00 | 0.1 | 55,246 | New | +$190,599.00 | <0.0001 | |
| Susquehanna International Group | $185,189.00 | 0.09 | 53,678 | -52.79% | -$207,089.59 | <0.0001 | |
| Goldman Sachs | $165,093.00 | 0.08 | 47,853 | +14.32% | +$20,686.22 | <0.0001 | |
| Citadel Advisors LLC | $129,568.00 | 0.07 | 37,556 | -28.75% | -$52,291.57 | <0.0001 | |
| Invesco | $126,508.00 | 0.06 | 36,669 | -13.5% | -$19,737.44 | <0.0001 | |
| T. Rowe Price | $122,000.00 | 0.06 | 35,181 | +6.83% | +$7,795.57 | <0.0001 | |
| Two Sigma Advisers LP | $121,440.00 | 0.06 | 35,200 | +66.83% | +$48,645.00 | <0.0001 | |
| Brighton Jones | $115,631.00 | 0.06 | 33,516 | 0% | +$0 | 0.01 | |
| Comerica | $103,500.00 | 0.05 | 30,000 | +20% | +$17,250.00 | <0.0001 | |
| American International Group | $103,507.00 | 0.05 | 30,002 | -0.85% | -$890.10 | <0.0001 | |
| Empirical Financial Services Llc D B A Empirical Wealth Management | $103,500.00 | 0.05 | 30,000 | 0% | +$0 | <0.01 | |
| Deutsche Bank | $97,863.00 | 0.05 | 28,366 | -3.71% | -$3,774.31 | <0.0001 | |
| Coldstream Wealth Management | $96,014.00 | 0.05 | 27,830 | -1.07% | -$1,035.01 | <0.01 | |
| JPMorgan Chase | $91,867.00 | 0.05 | 26,628 | -35.55% | -$50,670.37 | <0.0001 | |
| Millennium Management LLC | $91,825.00 | 0.05 | 26,616 | +150.62% | +$55,186.08 | <0.0001 | |
| Cypress Capital Group | $86,250.00 | 0.04 | 25,000 | -54.55% | -$103,500.00 | 0.01 | |
| The Manufacturers Life Insurance Company | $86,726.00 | 0.04 | 25,138 | 0% | +$0 | <0.0001 |